**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Expert Review DTC | **Project Code** | **PI4VVR059** |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Sanneke Koekkoek |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**October 2014**

**Project Type**

Expert Review (Video)

Downloadable Slides

Podcast

Other:

**Email Blast Included?**

Yes

No

Subject Line: New Expert Reviewin Relapsed/Refractory Differentiated Thyroid Cancer

**Number of E-Blasts**

Only One

Two  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**2014 Exp Review DTC**

Please add your content to the form below and remove any content that is irrelevant to your activity. If something gets updated, please update this document.

**\*\*\*DO NOT LIST “SEE ATTACHED DOCUMENT”.**

**This is the only copy document that should be sent to Design.\*\*\***

**Items highlighted in YELLOW should be completed by the Clinical Team**

**Items highlighted in TEAL should be determined at the Kickoff Meeting**

**In terms of LEAN, virtual products differ in that all sections should be complete prior to sending this form to Web (there is no minimum number of sections).**

1. **[Title---always italicized, no bold, no quotes]**

*Expert Review in Relapsed/Refractory Differentiated Thyroid Cancer*

1. **[Activity Date]**

**Release Date:**

October XX, 2014

**Expiration Date:**

October XX, 2015

1. **[Activity Overview]**

This CME-certified Expert Review features discussions on relapsed/refractory differentiated thyroid cancer (DTC).

1. **[Target Audience]**

This is activity is intended to meet the needs of practicing medical oncologists and other healthcare professionals involved in the treatment of patients with DTC.

1. **[Learning Objectives]**

After successful completion of this educational activity, participants should be able to:

* Describe the patients’ clinical presentation, key prognostic factors, and methods for making the diagnosis of DTC
* Apply recent advances to the treatment of patients with radioactive iodine refractory DTC, including integration of tyrosine kinase inhibitors
* Describe the role of molecular testing and the molecular targets known in DTC
* Identify appropriate strategies for evaluating patients with relapsed/refractory differentiated thyroid cancer

***[NOTE: learning objectives must be specific, measurable, attainable, relevant, time limited]***

1. **[Faculty Listing/Featured Experts/Discussants….Faculty Listing and Featured Experts sections are stacked, Discussants section is in-line]**

**Moderator**

Robert E. Coleman, MD, FRCP, FRCPE

Medical Director

prIME Oncology

**Discussants**

Rossella Elisei, MD

University of Pisa

Pisa, Italy

Barbara Jarzab, MD, PhD

MSC Memorial Cancer Center

Gliwice, Poland

1. **[Featured Abstracts/Discussion Topics/Activity Topics]**

**Discussion Topics:**

* Incidence, histologic classification, and prognosis for thyroid cancer
* Clinical presentation of a patient with thyroid cancer
* Prognostic factors and the methods for making the diagnosis of differentiated thyroid cancer (DTC)
* Role and role of molecular testing and the molecular targets known in DTC
* Initial treatment of DTC
* Definition, prognosis, and asymptomatic characteristics of patients with radioactive iodine refractory (RAI-R) DTC
* Treatment of RAI-R DTC
* Ongoing clinical trial for RAI-R DTC

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx) [[link to our Terms page]]

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 80% or higher.

1. **Provider**

This activity is provided by prIME Oncology.

1. **[Continuing Education---choose one]**

**US CME**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

[Insert ACCME logo]

prIME Oncology designates this enduring activity for a maximum of *XX AMA PRA Category 1 Credit(s)™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

\*\*All CME/CE verbiage should receive final approval from Regulatory/Compliance Manager

1. **Support Statement [ACCME—consult Cindy for proper verbiage and defer to BD for final approval of complete verbiage]**

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals

1. **[Disclosures]**

**CME**

**Disclosure of Relevant Financial Relationships**

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Elisei has disclosed that she has received consulting fees from AstraZeneca, Bayer, Exelixis, Genzyme, and Sobi. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Jarzab has disclosed that she has received consulting fees from AstraZeneca and Exelixis. She has also performed contracted research for AstraZeneca, Bayer, Eisai, Exelixis, Novartis, OxiGene, Pfizer, and Roche. She has also received fees for non-CME services from IPSEN and Novartis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

* Robert E. Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – expert testimony for Novartis
* Sanneke Koekkoek, RN (clinical content reviewer/planner) – no relevant financial relationships
* Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1. **[URL and Mobile App Name---give suggestions for URL name] \*\*\*Should be discussed and decided upon at the Kickoff Meeting.**

Insert URL here.

www.primeoncology.org/2014expertreviewDTC

\*\*Note: Do not include the name of the congress or society in the URL.

Page Title

Primary Keyword | Secondary Keyword

Insert Mobile App Name (restricted to 23 characters, including spaces. Conference names and abbreviations [ie, ASCO, ISHL] are appropriate to use. Do not include the location or year in the title. For Web activities, it is not necessary to include the type of activity [ie, CSP, Expert Review] in the title, as this will be indicated below the title. For Webcasts, use the same app title as was used for the live activity): **2014 Exp Review DTC**

Meta Description   
In this educational activity, expert faculty will provide a concise yet comprehensive discussion on the recent advances in the treatment of advanced refractory differentiated thyroid cancer, the emerging treatment options in this setting and the optimal integration of targeted therapy into the current treatment paradigm

Key Words/Key Phrases

Thyroid cancer

Differentiated thyroid cancer

DTC

Relapsed refractory thyroid cancer

TSH level

TKI

Radioactive iodine

RAI

Radioactive iodine refractory

RAI-R DTC

VEGFR

Kinase inhibitor

DECISION trial

Sorafenib

SELECT trial

Lenvatinib

vandetanib

1. **[Subject Line for Email Blast]**

A. Insert Email Blast Subject Line A copy here.

1. **[Email Blast Copy]**

Either list parts above that are to be included in the email blast or insert new (different) copy that is to be used in the email blast.

Example:

Title

Date/Time

Faculty

Topics

Target Audience

Learning Objectives

Continuing Education Statement

Credit Designation Statement

Disclosures

Providership (with logos)

Support (with no logos)

Fee Statement

1. **[Other]**

Please add any additional copy needed but not listed above with a description of what it is and where it is needed.

**16. [Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

Listing: 2014 Expert Review in Relapsed/Refractory Differentiated Thyroid Cancer

Description: Robert E. Coleman, MD, FRCP, FRCPE, from prIME Oncology; Rossella Elisei, MD, from University of Pisa, Pisa, Italy; and Barbara Jarzab, MD, PhD, MSC Memorial Cancer Center, Gliwice, Poland, discusses relapsed/refractory differentiated thyroid cancer.